Carcinoma of Unknown PrimaryPhase 3NCT00047125
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
A Phase 3 study testing radiation therapy in people with Carcinoma of Unknown Primary, run by European Organisation for Research and Treatment of Cancer - EORTC at 262 sites in 6 countries.
Trial summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. It is not yet known which regimen of radiation therapy is more effective in treating patients who have metastases to the lymph nodes in the neck. Read more about this study
- Who is it for?
- Ages 18 to 120 years, women only
- Conditions the study is for
- Carcinoma of Unknown Primary
- What is being tested?
- radiation therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 262 sitesin 6 countries
- Study dates
- Jul 2002to Jul 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed squamous cell carcinoma in cervical lymph node metastasis from an unknown primary tumor
- Histopathological grade WHO 1-3
- Pathological stage N1, N2a, N2b, or N3
- No N2c (i.e., bilateral metastatic nodes)
- No single node in supraclavicular fossa or submandibular area
- No evidence of primary tumor in head and neck, lung, esophageal, or other site
- Prior radical, radical modified, or extended radical dissection within the past 8 weeks
- Selective neck dissection allowed (surgeon must justify why standard procedure was not performed)
- No node excision alone
- R0 or R1 disease after dissection
- No distant metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Able and willing to complete quality of life questionnaires
- No other prior or concurrent malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
- No psychological, familial, sociological, or geographical condition that would preclude study compliance
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Concurrent chemotherapy allowed
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- See Disease Characteristics
Other
- No other prior therapy for carcinoma of unknown primary except neck dissection
Trial locations and contacts
262 sites in 6 countries.
262 sites in 6 countries
United States237 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44304
Radiation Oncology Associates of Albuquerque
Albuquerque, New Mexico, 87109
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
Harrington Cancer Center
Amarillo, Texas, 79106
St. John's Cancer Center at St. John's Medical Center
Anderson, Indiana, 46016
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0010
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Arlington Cancer Center
Arlington, Texas, 76012
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21215-1290
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
St. Agnes Cancer Center
Baltimore, Maryland, 21229
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Green Mountain Oncology Group
Bennington, Vermont, 05201
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Lourdes Regional Cancer Center
Binghamton, New York, 13905
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
Bloomington Hospital
Bloomington, Indiana, 47402
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02114
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
SUNY Downstate Medical Center
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Vermont Cancer Center at University of Vermont
Burlington, Vermont, 05405-0075
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599-7295
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013
Cancer Center at Christ Hospital
Cincinnati, Ohio, 45219
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45219
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
University Hospitals of Cleveland
Cleveland, Ohio, 44106
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Radiation Oncology Center
Clifton Springs, New York, 14432
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
Medical Center/John B. Amos Community Cancer Center
Columbus, Georgia, 31901
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
Mount Diablo Medical Center
Concord, California, 94524-4110
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
CCOP - Dayton
Dayton, Ohio, 45429
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, 80010
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07019
Dale and Frances Hughes Cancer Center
East Stroudsburg, Pennsylvania, 18301
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
East Syracuse, New York, 13057
St. Elizabeth Medical Center
Edgewood, Kentucky, 41017
John F. Kennedy Medical Center
Edison, New Jersey, 08818
McLaren Regional Cancer Center
Flint, Michigan, 48532-3685
21st Century Oncology - Fort Myers
Fort Myers, Florida, 33901-8082
California Cancer Center
Fresno, California, 93720
Saint Agnes Cancer Center
Fresno, California, 93720
Shands Cancer Center at the University of Florida Health Science Center
Gainesville, Florida, 32610-0385
University of Texas Medical Branch
Galveston, Texas, 77555-0209
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502-1628
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
Leo W. Jenkins Cancer Center of University Health Systems of Eastern Carolina
Greenville, North Carolina, 27835-6028
CCOP - Greenville
Greenville, South Carolina, 29615
RMH Regional Cancer Center
Harrisonburg, Virginia, 22801
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
MBCCOP - Hawaii
Honolulu, Hawaii, 96813
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
Comprehensive Cancer Institute
Huntsville, Alabama, 35801
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana, 46202
Methodist Cancer Center at Methodist Hospital
Indianapolis, Indiana, 46206-1367
Community Regional Cancer Care
Indianapolis, Indiana, 46219
West Tennessee Cancer Center at Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
Florida Radiation Oncology Group
Jacksonville, Florida, 32207
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236-5300
Oncology Institute of Greater Lafayette
Lafayette, Indiana, 47904
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89109
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756-0002
Central Baptist Hospital
Lexington, Kentucky, 40503
Cancer Center at Lexington Clinic
Lexington, Kentucky, 40504
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536-0293
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Monmouth Medical Center
Long Branch, New Jersey, 07740-6395
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1714
James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Louisville Radiation Oncology Center at Caritas Regional Cancer Center
Louisville, Kentucky, 40215
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410-1894
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center at Regional Medical Center of Hopkins County
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, 54449
Marshfield Clinic
Marshfield, Wisconsin, 54449
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Holmes Regional Medical Center
Melbourne, Florida, 32901-3276
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
University of Miami Sylvester Cancer Center
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176-2197
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
South Jersey Regional Cancer Center
Millville, New Jersey, 08332
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
Fairview University Medical Center - University Campus
Minneapolis, Minnesota, 55455
Trinity Cancer Care Center
Minot, North Dakota, 58701
MBCCOP - Gulf Coast
Mobile, Alabama, 36607
Montgomery Cancer Center
Montgomery, Alabama, 36106-3657
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital
Mount Holly, New Jersey, 08060
Ball Memorial Hospital Cancer Center
Muncie, Indiana, 47303-3499
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
Nashville, Tennessee, 37232-5671
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Hospital of St. Raphael
New Haven, Connecticut, 06511
Yale Comprehensive Cancer Center
New Haven, Connecticut, 06520-8040
Tulane Cancer Center at Tulane University Hospital and Clinic
New Orleans, Louisiana, 70112-2699
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Beth Israel Medical Center - Philipps Ambulatory Care Center
New York, New York, 10003
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, 10032
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Frank C. Love Cancer Institute at St. Anthony Hospital
Oklahoma City, Oklahoma, 73102
Oklahoma University Medical Center
Oklahoma City, Oklahoma, 73104
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha
Omaha, Nebraska, 68114-4199
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, 68198-7521
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806-2134
Bay Medical Center
Panama City, Florida, 32401
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Parma Community General Hospital
Parma, Ohio, 44129
Huntington Cancer Center at Huntington Hospital
Pasadena, California, 91105
NSMC Cancer Center
Peabody, Massachusetts, 01960
CCOP - Scott and White Hospital
Peoria, Illinois, 61602
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Abramson Cancer Center at University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104-4283
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141-3098
Foundation for Cancer Research and Education
Phoenix, Arizona, 85013
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Mercy Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15219
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Hillman Cancer Center at University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15236
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901-1490
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
Pomona, California, 91767
Atlantic City Medical Center
Pomona, New Jersey, 08240
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Medical Center of Princeton
Princeton, New Jersey, 08540
Roger Williams Medical Center
Providence, Rhode Island, 02908-4735
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
All Saints Cancer Center at All Saints Healthcare
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57709
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Bon Secours - St. Mary's Hospital
Richmond, Virginia, 23226
Massey Cancer Center at Virginia Commonwealth University
Richmond, Virginia, 23298-0058
Valley Hospital
Ridgewood, New Jersey, 07450
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905-0001
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Regional Radiation Oncology Center at Rome
Rome, Georgia, 30165
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan, 48073
Radiation Oncology Centers - Sacramento
Sacramento, California, 95816
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Peninsula Regional Medical Center
Salisbury, Maryland, 21801
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132
LDS Hospital
Salt Lake City, Utah, 84143
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811
Radiation Medical Group, Incorporated
San Diego, California, 92101
Naval Medical Center - San Diego
San Diego, California, 92134-3202
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
O'Connor Hospital
San Jose, California, 95128
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Sarasota Radiation and Medical Oncology Center
Sarasota, Florida, 34233
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Cancer Institute at Virginia Mason Medical Center
Seattle, Washington, 98111
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
North Shore Radiation Oncology
Setauket, New York, 11733
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99204
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
St. Louis University Hospital Cancer Center
St Louis, Missouri, 63110-0250
Siteman Cancer Center
St Louis, Missouri, 63110
Dixie Regional Medical Center
St. George, Utah, 84770
St. Joseph's Regional Cancer Center
Stockton, California, 95204
University Hospital at State University of New York - Upstate Medical University
Syracuse, New York, 13210
Tallahassee Memorial Hospital
Tallahassee, Florida, 32308
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
CCOP - Toledo Community Hospital
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
Torrance Memorial Medical Center
Torrance, California, 90505
David Grant Medical Center
Travis Air Force Base, California, 94535
Fox Chase Cancer Center at St. Francis Medical Center
Trenton, New Jersey, 08629
William Beaumont Hospital - Troy
Troy, Michigan, 48085
St. John Health System
Tulsa, Oklahoma, 74104
CCOP - Oklahoma
Tulsa, Oklahoma, 74136
DCH Cancer Treatment Center
Tuscaloosa, Alabama, 35401
Associated Radiologists, P.A.
Warren Township, New Jersey, 07059
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016
Waukesha Memorial Hospital Regional Cancer Center
Waukesha, Wisconsin, 53188
Schiffler Cancer Center at Wheeling Hospital
Wheeling, West Virginia, 26003
Wilkes-Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764-0001
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1082
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Riverhill Radiation Oncology
Yonkers, New York, 10701
Wellspan Health - York Cancer Center
York, Pennsylvania, 17403
Canada20 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
CHUS-Hopital Fleurimont
Fleurimont, Quebec, J1H 5N4
Northeastern Ontario Regional Cancer Centre at Regional Hospital of Sudbury Regional Hospital
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Doctor Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2L 4MI
McGill University
Montreal, Quebec, H2W 1S6
Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H 1C4
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Newfoundland Cancer Treatment and Research Foundation
St. John's, Newfoundland and Labrador, A1B 3V6
Northwestern Ontario Regional Cancer Care
Thunder Bay, Ontario, P7B 6V4
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Belgium2 sites
Cliniques Universitaires Saint-Luc
Brussels, 1200
Clinique Sainte Elisabeth
Namur, 5000
Switzerland1 site
Centre Hospitalier Universitaire Vaudois
Lausanne, CH-1011
About this study
Official title: Randomized Phase III Study On The Selection Of The Target Volume In Postoperative Radiotherapy For Cervical Lymph Node Metastases Of Squamous Cell Carcinoma From And Unknown Primary (CUP)
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. It is not yet known which regimen of radiation therapy is more effective in treating patients who have metastases to the lymph nodes in the neck.
PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have metastases to the lymph nodes in the neck from an unknown primary tumor.
Read the detailed description
OBJECTIVES:
- Compare the disease-free survival of patients with cervical lymph node metastases of squamous cell carcinoma from an unknown primary treated with selective irradiation vs extensive irradiation.
- Compare the overall survival of patients treated with these regimens.
- Compare the incidence of acute and late side effects in the head and neck region in patients treated with these regimens.
- Compare control of the neck and incidence of subsequent primary in the head and neck region in patients treated with these regimens.
- Compare quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to disease stage (N1-2a vs N2b-3), radiation technique (2D vs 3D conformal vs intensity-modulated), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo selective irradiation of the ipsilateral level of the neck once daily 5 days a week for 6 weeks.
- Arm II: Patients undergo extensive irradiation of the neck (nasopharyngeal, oropharyngeal, hypopharyngeal, and laryngeal mucosa and ipsilateral neck node areas on both sides of the neck) once daily 5 days a week for 6 weeks.
In both arms, treatment continues in the absence of unacceptable toxicity or disease progression.
Quality of life is assessed at baseline, at week 4, on the last day of therapy, and then every 3 months for 1 year.
Patients are followed at day 30, every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 7 years.
- Conditions
- Carcinoma of Unknown Primary
- Being tested
- radiation therapy
- Keywords
- newly diagnosed carcinoma of unknown primary, squamous cell carcinoma of unknown primary
- Medical subject headings
- Neoplasms, Unknown Primary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radiation therapyRadiation
| Study group | Role | What they receive |
|---|---|---|
| Selective irradiation | Experimental | Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks). Receives: Radiation: radiation therapy |
| Extensive irradiation + ipsilaterals levels | Active comparator | Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks). Receives: Radiation: radiation therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
disease-free survival
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startJul 2002
- Primary completionJul 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoma of Unknown PrimaryStudies of the same condition, open and under way.
- More trials run by European Organisation for Research and Treatment of Cancer - EORTCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 600 participants (actual)
Sponsor and investigators
- Sponsor type
- Research network
- Collaborators
- Radiation Therapy Oncology Group, NCIC Clinical Trials Group, Danish Head and Neck Cancer Group
- Responsible party
- Sponsor
- Investigators
- Vincent G. Gregoire, MD, PhD, Study chair, Cliniques universitaires Saint-Luc- Université Catholique de LouvainSharon A. Spencer, MD, Study chair, University of Alabama at BirminghamSamy El-Sayed, MD, FFR, FRCR, FRCP, Study chair, Ottawa Regional Cancer CentreEsat M. Ozsahin, MD, PhD, Study chair, Centre Hospitalier Universitaire VaudoisCai Grau, MD, Study chair, Aarhus Universitetshospital - Aarhus Sygehus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00047125
- Sponsor's protocol ID
- EORTC-24001-22005
- Other IDs
- EORTC-24001, EORTC-22005, DAHANCA-EORTC-24001, CAN-NCIC-EORTC-24001, RTOG-EORTC-24001
- Status last verified
- Jul 2018
- First submitted
- 3 Oct 2002
- Last updated
- 9 Jul 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Phase III Study On The Selection Of The Target Volume In Postoperative Radiotherapy For Cervical Lymph Node Metastases Of Squamous Cell Carcinoma From And Unknown Primary (CUP)
- ClinicalTrials.gov ID
- NCT00047125
- Acronym / sponsor ID
- EORTC-24001-22005
- Conditions
- Carcinoma of Unknown Primary
- Keywords
- newly diagnosed carcinoma of unknown primary, squamous cell carcinoma of unknown primary
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 600 participants (actual)
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Collaborators
- Radiation Therapy Oncology Group, NCIC Clinical Trials Group, Danish Head and Neck Cancer Group
- Study start
- Jul 2002
- Primary completion
- Jul 2004 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. It is not yet known which regimen of radiation therapy is more effective in treating patients who have metastases to the lymph nodes in the neck.
PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have metastases to the lymph nodes in the neck from an unknown primary tumor.
Detailed description
OBJECTIVES:
- Compare the disease-free survival of patients with cervical lymph node metastases of squamous cell carcinoma from an unknown primary treated with selective irradiation vs extensive irradiation.
- Compare the overall survival of patients treated with these regimens.
- Compare the incidence of acute and late side effects in the head and neck region in patients treated with these regimens.
- Compare control of the neck and incidence of subsequent primary in the head and neck region in patients treated with these regimens.
- Compare quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to disease stage (N1-2a vs N2b-3), radiation technique (2D vs 3D conformal vs intensity-modulated), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo selective irradiation of the ipsilateral level of the neck once daily 5 days a week for 6 weeks.
- Arm II: Patients undergo extensive irradiation of the neck (nasopharyngeal, oropharyngeal, hypopharyngeal, and laryngeal mucosa and ipsilateral neck node areas on both sides of the neck) once daily 5 days a week for 6 weeks.
In both arms, treatment continues in the absence of unacceptable toxicity or disease progression.
Quality of life is assessed at baseline, at week 4, on the last day of therapy, and then every 3 months for 1 year.
Patients are followed at day 30, every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 7 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Selective irradiation | Experimental | Radiation: radiation therapyIrradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks). |
| Extensive irradiation + ipsilaterals levels | Active comparator | Radiation: radiation therapyIrradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks). |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radiation therapy | Radiation | Extensive irradiation + ipsilaterals levels, Selective irradiation |
Primary outcome
disease-free survival
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2018.
Related trials for Carcinoma of Unknown Primary
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Ampulla of Vater Carcinoma, Appendix Carcinoma
Active, not recruitingPhase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Active, not recruitingPhase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Anal Carcinoma, Bladder Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent G. Gregoire, MD, PhD study chair
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sharon A. Spencer, MD study chair
University of Alabama at Birmingham
Samy El-Sayed, MD, FFR, FRCR, FRCP study chair
Ottawa Regional Cancer Centre
262 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing radiation therapy in people with Carcinoma of Unknown Primary, run by European Organisation for Research and Treatment of Cancer - EORTC at 262 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 262 sites in United States, Canada, Belgium, Denmark, Netherlands and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
disease-free survival. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2018.